US pharmaceutical giant Pfizer has signed a $ 5.29 billion deal with the American government to deliver 10 million doses of his new Oral antiviral drug Covid-19, Paxlovid.
“This promising treatment could help speed up our path out of this pandemic by offering another life-saving tool for people who to get sick with COVID-19,” Saverio Becerra, secretary of the United States Department of Health and human services, he said on Thursday.
Under the agreement, Pfizer will deliver approximately 10 million courses of its antiviral drug for the treatment of Covid-19 a cost of 5.29 billion dollars to the US taxpayer. The company says cut the chance of hospitalization or death for adults a risk of 89% severe disease.
The pharmaceutical giant expects to produce 180,000 courses of the treatment at the end of December, and intends to produce at least 50 million by the end of next year.
In a statement released after the agreement was announced, US President Joe Biden said the courses would be available from the end of the year. “My administration is making the necessary preparations now for ensure these treatments will be easily accessible and free “, he added, but reiterated that “vaccines remain our strongest tool “ against the virus.
The Biden administration has also signed a $ 2.2 billion deal with Merck and Ridgeback Biotherapies for their Covid-19 pill. However, that drug, Molnupiravir, is not as effective as Pfizer’s oral treatment, alone halving the chance of dying or be hospitalized in hospital in patients susceptible to severe illness.
On Thursday, Anglo-Swedish health giant AstraZeneca said its Covid-19 preventative drug delivered as a blow in the arm, offered at 83% protection over six months, providing an extra boost in the fight against COVID-19.
If you like this story, share it with a friend!
Read More: World News
Source RT News.
Denial of any Responsibility!
AsumeTech is a News Source that Publishes News from its Editorial Team and the Automatic News Aggregation around the News Media. The Content is aggregated from RT News; each piece of Content includes the hyperlink to its Source. We have just rearranged that in our platform for Educational Purposes only. All the Copyrights and Trademarks belong to their Rightful Owners and all Materials to their Authors. If you do not want us to publish your materials on our Website, please get in touch with us by email – firstname.lastname@example.org; we will remove the Content from our Website.